Physician profile
Robert Scaffidi
NPI 1538397823
$4,359.07
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,939 · 2020: $820 · 2021: $1,466 · 2022: $134.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $720.42 | 2019-2022 | |
| Amgen INC. | $502.68 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $490.36 | 2019-2022 | |
| Gilead Sciences, INC. | $449.04 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.42 | 2019-2021 | |
| Lilly USA, LLC | $272.32 | 2019-2021 | |
| Novo Nordisk INC | $223.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $204.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $193.26 | 2019-2021 | |
| Abbvie INC. | $170.86 | 2021-2022 | |
| Glaxosmithkline, LLC. | $157.77 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.32 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.47 | 2019-2020 | |
| Dynavax Technologies Corporation | $50.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.77 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.97 | 2019-2020 | |
| Amarin Pharma, INC. | $38.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.23 | 2021 | |
| Ethicon US, LLC | $31.08 | 2019 | |
| Insmed, INC. | $25.15 | 2021 | |
| Sanofi Pasteur INC. | $23.99 | 2019 | |
| Ibsa Pharma INC. | $21.23 | 2019 | |
| Eisai INC. | $20.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.41 | 2019 | |
| Genentech USA, INC. | $17.92 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scaffidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.